Replies to post #565490 on NorthWest Biotherapeutics Inc (NWBO)

[vator]

Shareholders had no clue what was being presented the day before. Wall Street had no idea. They needed to prepare Walk Street with an idea that dats about to be released would be big for GBM. They needed to hit the cable business networks.

Management knew the data for about two years and produced a clown show.

Instead pretty much silence with a blogger printing “Failure” of the trial and this got picked up by other sites and even cancer publications.

[vator]

I also have no idea when they started shopping the “C” shares and what impact that had on the action of the shares big it was prior to May 10th that would have been pretty stupid.

[vator]

And your loss that day is only compounded by shares being issued at a much lower price when they should have been offered during a rise in price from that day.

Incredibly incompetent management.

[FeMike]

I know you are long and have a problem with the way management runs this Company. Please explain to a lay man what could have been done to prevent May 10th or maintained the $2.00+/- share price.

Company could have updated the ClinicalTrials.gov website to show the new endpoints much earlier.

Company could have issued a TLD PR just before the conference to show it met the new endpoints stat sig.

Company could have given guidance to LL to not allow the first slide addressing results in that presentation to say the trial failed its primary endpoint which is exactly when the stock price plummeted.

Company could have proactively PRd the presentation and its subject instead of reacting to an NYAS bulletin that selectively disclosed the presentation subject.

There are lots of things the company could have and should have done better. Instead they just ran straight into the iceberg and said “huh….I wonder why the ship sinking”.